<div style="margin: 0px 22px 20px; padding: 0px; box-sizing: border-box; border: none; font-family: Roboto, Arial, sans-serif; font-size: 14px;"><figure style="margin: 0px; padding: 0px; box-sizing: border-box; border: none;"><div style="margin: 0px; padding: 0px 0px 551.25px; box-sizing: border-box; display: flex; width: 980px; position: relative; background-color: #c4c4c4;"><img src="http://s.rfi.fr/media/display/50388864-48d8-11ea-babc-005056a917b9/w:900/p:16×9/rdxz.jpg" alt="图为美国冠状病毒新药瑞德西韦化学序列图谱" data-image-dataset="[{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:170\\/p:16×9\\/rdxz.jpg","width":170,"height":96,"name":"170×96"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:200\\/p:16×9\\/rdxz.jpg","width":200,"height":113,"name":"200×113"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:240\\/p:16×9\\/rdxz.jpg","width":240,"height":135,"name":"240×135"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:280\\/p:16×9\\/rdxz.jpg","width":280,"height":158,"name":"280×158"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:310\\/p:16×9\\/rdxz.jpg","width":310,"height":174,"name":"310×174"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:400\\/p:16×9\\/rdxz.jpg","width":400,"height":225,"name":"400×225"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:480\\/p:16×9\\/rdxz.jpg","width":480,"height":270,"name":"480×270"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:650\\/p:16×9\\/rdxz.jpg","width":650,"height":366,"name":"650×366"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:900\\/p:16×9\\/rdxz.jpg","width":900,"height":506,"name":"900×506"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:980\\/p:16×9\\/rdxz.jpg","width":980,"height":551,"name":"980×551"},{"url":"http:\\/\\/s.rfi.fr\\/media\\/display\\/50388864-48d8-11ea-babc-005056a917b9\\/w:1240\\/p:16×9\\/rdxz.jpg","width":1240,"height":698,"name":"1240×698"}]" style="position: absolute; width: 980px; height: 551.25px; transition: opacity 0.3s ease 0s; font-size: 14pt;" /></div><figcaption style="font-size: 1.5rem; color: #9a9a9a; padding: 8px 0px;"><span style="font-size: 14pt;">图为美国冠状病毒新药瑞德西韦化学序列图谱 </span><span style="margin: 0px 2px; font-size: 14pt;">网络照片</span></figcaption></figure></div><div style="margin: 0px 22px 22px; padding: 0px; box-sizing: border-box; border: none; font-family: Roboto, Arial, sans-serif; font-size: 14px;"><div style="margin: 0px; padding: 0px; box-sizing: border-box; border: none; display: flex; -webkit-box-pack: start; justify-content: flex-start; -webkit-box-align: center; align-items: center; flex-wrap: wrap; font-size: 1.5rem;"><div style="margin: 0px; padding: 0px; box-sizing: border-box; border: none; display: flex; -webkit-box-pack: start; justify-content: flex-start; flex-wrap: wrap;"><div style="margin: 0px 0px 3px; padding: 0px; box-sizing: border-box; border: none; display: flex; -webkit-box-align: center; align-items: center; color: #9a9a9a; flex-wrap: wrap; line-height: 1.4;"><span style="margin: 0px 5px 0px 0px; font-size: 14pt;">作者：</span><a href="http://www.rfi.fr/cn/contenu/20190916-%E5%B0%8F%E5%B1%B1" title="小山" style="margin: 0px 5px 0px 0px; padding: 0px; box-sizing: border-box; border: none; color: #e2001a; text-decoration-line: none; outline: none;"><span style="font-size: 14pt;">小山</span></a></div></div></div></div><p style="margin-right: auto; margin-bottom: 28px; margin-left: auto; padding: 0px; box-sizing: border-box; border: none; font-size: 1.9rem; font-weight: 700; line-height: 1.5; max-width: 850px; font-family: Roboto, Arial, sans-serif;"><span style="font-size: 14pt;">武汉肺炎疫情持续蔓延，相关药物研究引起各界关注。中国科学院武汉病毒研究所早前以抗伊波拉病毒药物瑞德西韦，可抑制武汉肺炎病毒为由申报专利。对此，美国吉利德公司回应称，在2016年已就该药物对冠状病毒的用途，在全球申请专利，包括中国，但中国的申请还有待批准。</span></p><div style="margin: 0px auto 20px; padding: 0px; box-sizing: border-box; border: none; max-width: 850px; font-family: Roboto, Arial, sans-serif; font-size: 14px;"><div style="margin: 0px; padding: 0px; box-sizing: border-box; position: relative; display: flex; -webkit-box-pack: center; justify-content: center; float: right;"><div style="margin: 0px; padding: 0px 0px 0px 30px; box-sizing: content-box; border: none; -webkit-box-pack: center; justify-content: center; flex-wrap: wrap; display: flex; width: 300px;"></div></div><p style="margin-bottom: 28px; padding: 0px; box-sizing: border-box; border: none; font-size: 1.7rem; line-height: 1.4;"><span style="font-size: 14pt;">据东网今天报道说，武汉肺炎：华研究所抢注专利，美国公司中国申请未批。</span></p><p style="margin-bottom: 28px; padding: 0px; box-sizing: border-box; border: none; font-size: 1.7rem; line-height: 1.4;"><span style="font-size: 14pt;">该报道称，吉利德公司回应武汉病毒研究所申报药物专利。</span></p><p style="margin-bottom: 28px; padding: 0px; box-sizing: border-box; border: none; font-size: 1.7rem; line-height: 1.4;"><span style="font-size: 14pt;">武汉肺炎疫情持续蔓延，相关药物研究引起各界关注。中国科学院武汉病毒研究所早前以抗伊波拉病毒药物瑞德西韦，可抑制武汉肺炎病毒为由申报专利。对此，美国吉利德公司回应称，在2016年已就该药物对冠状病毒的用途，在全球申请专利，包括中国，但中国的申请还有待批准。</span></p><p style="margin-bottom: 28px; padding: 0px; box-sizing: border-box; border: none; font-size: 1.7rem; line-height: 1.4;"><span style="font-size: 14pt;">据吉利德公司表示，已注意到该研究所就相关药物的应用申请专利的情况，但目前任何强制许可等还言之尚早，其所关注的是尽快确认该药物对新型冠状病毒的潜在治疗效果，加快生产供应，以应对未来潜在的供给需求。</span></p><div id="tms-ad-inread-7653684420101543" data-tms-ad-type="inread" data-tms-ad-provider="teads" data-tms-ad-status="idle" style="margin: 0px auto; padding: 0px; box-sizing: border-box; border: none; max-width: 530px; line-height: 0; font-size: 0px; overflow: hidden;"><div style="margin: 0px; padding: 0px; box-sizing: border-box; border: none;"></div></div><p style="margin-bottom: 28px; padding: 0px; box-sizing: border-box; border: none; font-size: 1.7rem; line-height: 1.4;"><span style="font-size: 14pt;">对于武汉病毒研究所的专利申请，吉利德公司认为其无权干涉专利局是否向中国研究人员授予专利，而该研究所的申请是在吉利德提交申请的三年多时间之后提交的；并强调他们将在18个月后发布专利的申请内容。</span></p><p style="margin-bottom: 28px; padding: 0px; box-sizing: border-box; border: none; font-size: 1.7rem; line-height: 1.4;"><span style="font-size: 14pt;">东网说，惟该研究所至今仍未回应相关事件。</span></p></div>